Effects of 3 years treatment with once-yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients

S. Gamsjaeger, B. Hofstetter, E. Zwettler, Robert R. Recker, J. A. Gasser, E. F. Eriksen, K. Klaushofer, E. P. Paschalis

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Once-yearly administration of intravenous zoledronic acid for 3 years in humans affects the kinetics of matrix filling in by mineral, independent of bone turnover. Introduction: Yearly 5-mg infusions of zoledronic acid (ZOL) for 3 years have shown pronounced antifracture efficacy. The purpose of the present study was to test whether ZOL affects the kinetics of forming bone material properties maturation. Methods: Iliac crest biopsies from the HORIZON-PFT clinical trial were analyzed by Raman microspectroscopy in actively bone-forming surfaces as a function of tissue age in trabecular and osteonal bone, to determine ZOL's effect on bone material quality indices maturation kinetics. Results: Mineral/matrix ratio increased in both groups as a function of tissue age, at both osteonal- and trabecular-forming surfaces; ZOL exhibiting the greatest increase in the trabecular surfaces only. The proteoglycan content showed a dependency on tissue age in both trabecular and osteonal surfaces, with ZOL exhibiting lower values in the tissue age 8-22 days in the trabecular surfaces. Mineral crystallinity (crystallite length and thickness) showed a dependence on tissue age, with ZOL exhibiting lower crystallite length compared with placebo only in the 8- to 22-day-old tissue at trabecular surfaces, while crystal thickness was lower in the 1- to 5-day-old tissue at both osteonal and trabecular surfaces. Conclusions: The results of the present study suggest that once-yearly administration of intravenous ZOL for 3 years in humans does not exert any adverse effects on the evolution of bone material properties at actively forming osteonal and trabecular surfaces, while it may have a beneficial effect on the progression of the mineral-to-matrix ratio and mineral maturity bone quality indices.

Original languageEnglish
Pages (from-to)339-347
Number of pages9
JournalOsteoporosis International
Volume24
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

zoledronic acid
Bone Matrix
Minerals
Bone and Bones
Intravenous Administration
Therapeutics
Bone Remodeling
Proteoglycans

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Effects of 3 years treatment with once-yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients. / Gamsjaeger, S.; Hofstetter, B.; Zwettler, E.; Recker, Robert R.; Gasser, J. A.; Eriksen, E. F.; Klaushofer, K.; Paschalis, E. P.

In: Osteoporosis International, Vol. 24, No. 1, 01.2013, p. 339-347.

Research output: Contribution to journalArticle

Gamsjaeger, S, Hofstetter, B, Zwettler, E, Recker, RR, Gasser, JA, Eriksen, EF, Klaushofer, K & Paschalis, EP 2013, 'Effects of 3 years treatment with once-yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients', Osteoporosis International, vol. 24, no. 1, pp. 339-347. https://doi.org/10.1007/s00198-012-2202-8
Gamsjaeger, S. ; Hofstetter, B. ; Zwettler, E. ; Recker, Robert R. ; Gasser, J. A. ; Eriksen, E. F. ; Klaushofer, K. ; Paschalis, E. P. / Effects of 3 years treatment with once-yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients. In: Osteoporosis International. 2013 ; Vol. 24, No. 1. pp. 339-347.
@article{65fabb32cea84a5f89674d4e0ff4f23c,
title = "Effects of 3 years treatment with once-yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients",
abstract = "Once-yearly administration of intravenous zoledronic acid for 3 years in humans affects the kinetics of matrix filling in by mineral, independent of bone turnover. Introduction: Yearly 5-mg infusions of zoledronic acid (ZOL) for 3 years have shown pronounced antifracture efficacy. The purpose of the present study was to test whether ZOL affects the kinetics of forming bone material properties maturation. Methods: Iliac crest biopsies from the HORIZON-PFT clinical trial were analyzed by Raman microspectroscopy in actively bone-forming surfaces as a function of tissue age in trabecular and osteonal bone, to determine ZOL's effect on bone material quality indices maturation kinetics. Results: Mineral/matrix ratio increased in both groups as a function of tissue age, at both osteonal- and trabecular-forming surfaces; ZOL exhibiting the greatest increase in the trabecular surfaces only. The proteoglycan content showed a dependency on tissue age in both trabecular and osteonal surfaces, with ZOL exhibiting lower values in the tissue age 8-22 days in the trabecular surfaces. Mineral crystallinity (crystallite length and thickness) showed a dependence on tissue age, with ZOL exhibiting lower crystallite length compared with placebo only in the 8- to 22-day-old tissue at trabecular surfaces, while crystal thickness was lower in the 1- to 5-day-old tissue at both osteonal and trabecular surfaces. Conclusions: The results of the present study suggest that once-yearly administration of intravenous ZOL for 3 years in humans does not exert any adverse effects on the evolution of bone material properties at actively forming osteonal and trabecular surfaces, while it may have a beneficial effect on the progression of the mineral-to-matrix ratio and mineral maturity bone quality indices.",
author = "S. Gamsjaeger and B. Hofstetter and E. Zwettler and Recker, {Robert R.} and Gasser, {J. A.} and Eriksen, {E. F.} and K. Klaushofer and Paschalis, {E. P.}",
year = "2013",
month = "1",
doi = "10.1007/s00198-012-2202-8",
language = "English",
volume = "24",
pages = "339--347",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "1",

}

TY - JOUR

T1 - Effects of 3 years treatment with once-yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients

AU - Gamsjaeger, S.

AU - Hofstetter, B.

AU - Zwettler, E.

AU - Recker, Robert R.

AU - Gasser, J. A.

AU - Eriksen, E. F.

AU - Klaushofer, K.

AU - Paschalis, E. P.

PY - 2013/1

Y1 - 2013/1

N2 - Once-yearly administration of intravenous zoledronic acid for 3 years in humans affects the kinetics of matrix filling in by mineral, independent of bone turnover. Introduction: Yearly 5-mg infusions of zoledronic acid (ZOL) for 3 years have shown pronounced antifracture efficacy. The purpose of the present study was to test whether ZOL affects the kinetics of forming bone material properties maturation. Methods: Iliac crest biopsies from the HORIZON-PFT clinical trial were analyzed by Raman microspectroscopy in actively bone-forming surfaces as a function of tissue age in trabecular and osteonal bone, to determine ZOL's effect on bone material quality indices maturation kinetics. Results: Mineral/matrix ratio increased in both groups as a function of tissue age, at both osteonal- and trabecular-forming surfaces; ZOL exhibiting the greatest increase in the trabecular surfaces only. The proteoglycan content showed a dependency on tissue age in both trabecular and osteonal surfaces, with ZOL exhibiting lower values in the tissue age 8-22 days in the trabecular surfaces. Mineral crystallinity (crystallite length and thickness) showed a dependence on tissue age, with ZOL exhibiting lower crystallite length compared with placebo only in the 8- to 22-day-old tissue at trabecular surfaces, while crystal thickness was lower in the 1- to 5-day-old tissue at both osteonal and trabecular surfaces. Conclusions: The results of the present study suggest that once-yearly administration of intravenous ZOL for 3 years in humans does not exert any adverse effects on the evolution of bone material properties at actively forming osteonal and trabecular surfaces, while it may have a beneficial effect on the progression of the mineral-to-matrix ratio and mineral maturity bone quality indices.

AB - Once-yearly administration of intravenous zoledronic acid for 3 years in humans affects the kinetics of matrix filling in by mineral, independent of bone turnover. Introduction: Yearly 5-mg infusions of zoledronic acid (ZOL) for 3 years have shown pronounced antifracture efficacy. The purpose of the present study was to test whether ZOL affects the kinetics of forming bone material properties maturation. Methods: Iliac crest biopsies from the HORIZON-PFT clinical trial were analyzed by Raman microspectroscopy in actively bone-forming surfaces as a function of tissue age in trabecular and osteonal bone, to determine ZOL's effect on bone material quality indices maturation kinetics. Results: Mineral/matrix ratio increased in both groups as a function of tissue age, at both osteonal- and trabecular-forming surfaces; ZOL exhibiting the greatest increase in the trabecular surfaces only. The proteoglycan content showed a dependency on tissue age in both trabecular and osteonal surfaces, with ZOL exhibiting lower values in the tissue age 8-22 days in the trabecular surfaces. Mineral crystallinity (crystallite length and thickness) showed a dependence on tissue age, with ZOL exhibiting lower crystallite length compared with placebo only in the 8- to 22-day-old tissue at trabecular surfaces, while crystal thickness was lower in the 1- to 5-day-old tissue at both osteonal and trabecular surfaces. Conclusions: The results of the present study suggest that once-yearly administration of intravenous ZOL for 3 years in humans does not exert any adverse effects on the evolution of bone material properties at actively forming osteonal and trabecular surfaces, while it may have a beneficial effect on the progression of the mineral-to-matrix ratio and mineral maturity bone quality indices.

UR - http://www.scopus.com/inward/record.url?scp=84872301464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872301464&partnerID=8YFLogxK

U2 - 10.1007/s00198-012-2202-8

DO - 10.1007/s00198-012-2202-8

M3 - Article

VL - 24

SP - 339

EP - 347

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 1

ER -